[NEWSMP] While the performances of global big pharma companies have been mixed, they are increasing their growth rate, emerging from the impact of COVID-19.
According to the first quarter report of major global big pharma companies compiled by Newsmp, Novo Nordisk and Lilly maintained strong growth, enjoying a boom thanks to obesity therapy. On the other hand, Pfizer and Moderna have seen declines in sales.
Among the 17 big pharma companies compiled by Newsmp, Lilly saw the largest growth in sales. With the addition of Zepbound in the fourth quarter of last year, Lilly grew 26.0% in the first quarter of this year.
Novo Nordisk, which significantly increased sales with its semaglutide franchise including Wegovy and Ozempic, continued its strong growth of 22.5% in the first quarter.
Amgen also recorded 22.0% growth, benefiting from the merger, while Astrazeneca and GSK achieved double-digit growth rates of 16.5% and 10.0%, respectively.
Next, Novartis and Merck posted near double-digit growth at 9.5% and 8.9%, respectively. Organon and Gilead saw growth rates above 5%.
In addition, BMS, Sanofi, Johnson & Johnson, Abbvie reported modest increases in sales compared to the same period last year.
On the other hand, Moderna, which has yet to commercialize a product other than a COVID-19 vaccine, has seen its sales plummet by more than 90% as a result of the COVID-19 endemic.
Pfizer also saw its sales plunge nearly 20% because of the endemic, while Biogen and Roche saw sales drop more than 5% year over year.
